Pregnan t and nursing women. Products, Dosage, and Mode of Administration: Investigational Products Dosage Mode of Administration Aldoxorubicin HCl 80 mg/m2 or 30 mg/m2 (induction); 60 mg/m2 (maintenance) IV ALT -803 10 µg/kg SC ETBX -011 1 × 1011 VP/dose SC ETBX -051 1 × 1011 VP/dose SC ETBX -061 1 × 1011 VP/dose SC GI-4000 40 YU/dose SC GI-6207 40 YU/dose SC GI-6301 40 YU/dose SC haNK cells 2 × 109 cells/dose IV Approved Products Dosage Mode of Administration Avelumab 10 mg/kg IV Bevacizumab 5 mg/kg IV Capecitabine 650 mg/m2 PO BID Cisplatin 40 mg/m2 IV Cyclophosphamide 50 mg PO BID 5-FU 1500 mg/m2 85- to 96-hour continuous IV infusion Leucovorin 20 mg/m2 IV bolus Confidential and Proprietary 17 NANT TNBC Vaccine NantKwest, Inc. Clinical Trial Protocol: QUILT -3.067 Approved Products Dosage Mode of Administration Nab-paclitaxel 125 mg (induction); 100 mg (maintenance) IV Omega -3-acid ethyl esters 5 g PO SBRT 8 Gy maximum (exact dose to be determined by the radiation oncologist) External beam radiation Duration of Treatment: • Induction phase: 8 weeks (minimum) to 1 year (maximum). • Maintenance phase: Up to 1 year.